Study guide
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements
Key Takeaways Explain This Topic AI
KDOQI 2020 was developed jointly by the National Kidney Foundation and the Academy of Nutrition and Dietetics and covers adults with CKD stages 1–5, 5D and post-transplant.
Level 1 statements read 'we recommend' and Level 2 statements 'we suggest'; evidence is graded A (high) to D (very low); ungraded OPINION statements reflect expert consensus.
KDOQI 2020 recommends the 7-point Subjective Global Assessment for adults on dialysis (1B) and suggests a 3-day food record covering dialysis and non-dialysis days (2C).
KDOQI 2020 suggests at least a 3-month trial of oral nutritional supplements before escalation, and a trial of IDPN for maintenance hemodialysis patients with PEW whose needs are not met orally or enterally (2C).
KDOQI 2020 finds insufficient evidence to recommend plant versus animal protein (1B) and suggests not routinely supplementing zinc or selenium (2C).
Last updated: September 2026
Why this guideline anchors the exam
The KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update (Ikizler et al., American Journal of Kidney Diseases 2020;76(3 Suppl 1)) replaced the 2000 KDOQI nutrition guideline. It was a joint project of the National Kidney Foundation (NKF) and the Academy of Nutrition and Dietetics , whose Evidence Analysis Center ran the systematic reviews. The Academy also publishes it on the Evidence Analysis Library (EAL) as the CKD evidence-based nutrition practice guideline. The CSR outline names "nutrition guidelines (e.g., AND, KDOQI, KDIGO)" in Domain 3. A task statement asks you to utilize evidence-based protocols and guidelines (i.e., KDOQI) to deliver standardized care .
The guideline covers adults with CKD stages 1–5, stage 5D (on dialysis) and post-transplant . It does not cover children, and it leaves many areas to clinical judgment where evidence is thin.
How statements are graded
KDOQI 2020 used the GRADE method:
Strength: Level 1, "we recommend" , means most patients should receive the course of action and it could serve as a performance measure. Level 2, "we suggest" , means different choices suit different patients and shared decision-making is expected.
Quality of evidence: A (high), B (moderate), C (low), D (very low).
OPINION: an ungraded statement written when evidence was absent or too weak but the work group judged guidance important. It usually describes routine practice ("it is reasonable to…").
So "1A" is a strong recommendation on high-quality evidence, "2C" is a weak suggestion on low-quality evidence, and OPINION is expert consensus.
- Key statements by guideline area
- 1. Nutrition assessment
- Statement Grade
- Routine nutrition screening at least biannually in CKD 3–5D or post-transplant OPINION
Comprehensive assessment by an RDN within the first 90 days of dialysis, annually , or when screening or a referral indicates OPINION
- Bioimpedance (preferably multi-frequency) in maintenance HD, done at least 30 minutes after the session 2C
- DXA as the gold standard for body composition despite volume effects OPINION
Weight and BMI at least monthly on dialysis, every 3 months in CKD 4–5 or post-transplant, every 6 months in CKD 1–3 OPINION
- BMI alone is not enough to diagnose PEW unless it is very low ( below 18 kg/m² ) OPINION
- Serum albumin predicts hospitalization and mortality in maintenance HD 1A
- Handgrip strength as an indicator of protein-energy and functional status when baseline data exist 2B
- 7-point SGA is valid and reliable for adults on dialysis 1B
- Malnutrition Inflammation Score may be used in maintenance HD or post-transplant 2C
- 3-day food record covering dialysis and non-dialysis days as the preferred intake method 2C
- Assess factors beyond intake: medications, knowledge, beliefs, food access, depression, cognition OPINION
- 2. Medical nutrition therapy
An RDN, in close collaboration with a physician or other provider, should provide MNT in CKD 1–5D to improve nutrition status and slow progression ( 1C ).
MNT should be tailored and monitored through appetite, intake, weight, labs, anthropometrics and physical findings (OPINION).
3. Protein and energy
Population Statement Grade
CKD 3–5, metabolically stable, no diabetes LPD 0.55–0.60 g/kg/day , or VLPD 0.28–0.43 g/kg/day plus ketoacid or amino acid analogues (to meet 0.55–0.60), under close supervision 1A (ESKD/death); 2C (quality of life)
- CKD 3–5 with diabetes 0.6–0.8 g/kg/day OPINION
- Maintenance HD or PD, metabolically stable 1.0–1.2 g/kg/day 1C (HD); OPINION (PD)
- Dialysis with diabetes 1.0–1.2 g/kg/day, possibly higher to help glycemic control OPINION
- CKD 1–5D or post-transplant, stable Energy 25–35 kcal/kg/day 1C
- Protein type Insufficient evidence to recommend plant versus animal protein 1B
- Dietary pattern Mediterranean diet may improve lipids (CKD 1–5 and post-transplant) 2C
- Dietary pattern More fruits and vegetables may lower weight, BP and net acid production (CKD 1–4) 2C
- 4. Nutritional supplementation
Oral supplements: at least a 3-month trial for patients at risk of or with PEW when counseling alone does not meet needs ( 2D ).
Enteral tube feeding: a trial is reasonable when intake stays inadequate despite counseling and oral supplements (OPINION).
TPN or IDPN: a trial of TPN in CKD 1–5 and IDPN in maintenance HD for PEW when needs cannot be met orally or enterally ( 2C ).
Amino acid dialysate (PD): not suggested as a general strategy, but a trial is reasonable when needs cannot be met otherwise (OPINION).
Long-chain omega-3s: not routinely prescribed to lower mortality or cardiovascular events in HD (2C/2B) or to improve access patency. They may be used at 1.3–4 g/day to lower triglycerides in HD (2C).
5. Micronutrients
Encourage a diet meeting the RDA for vitamins and minerals. Consider a multivitamin when intake is inadequate; on dialysis, supplement water-soluble vitamins and essential trace elements if intake stays poor (OPINION).
Folate: do not routinely supplement to lower homocysteine ( 1A , no cardiovascular benefit), but do correct folate or B12 deficiency ( 2B ).
Vitamin C: for patients at risk of deficiency, supplementing to at least 90 mg/day (men) or 75 mg/day (women) is reasonable (OPINION).
Vitamin D: correct 25(OH)D deficiency with cholecalciferol or ergocalciferol ( 2C ).
Vitamins A and E: do not routinely supplement on dialysis because of toxicity risk (OPINION).
Vitamin K: no vitamin K supplements for patients on warfarin-type anticoagulants (OPINION).
Zinc and selenium: do not routinely supplement ( 2C ).
6. Electrolytes
- Topic Statement Grade
- Acid load Increase fruit and vegetable intake to reduce net acid production in CKD 1–4 2C
- Bicarbonate Reduce net acid production with bicarbonate or citrate supplements in CKD 3–5D 1C
- Bicarbonate target Keep serum bicarbonate at 24–26 mmol/L OPINION
Calcium Total elemental calcium 800–1,000 mg/day (diet, supplements and calcium binders) in CKD 3–4 not on active vitamin D 2B
- Phosphorus Adjust dietary phosphorus to keep serum phosphate in the normal range (CKD 3–5D) 1B
- Phosphorus source Consider bioavailability (animal, vegetable, additives) OPINION
- Post-transplant hypophosphatemia High-phosphorus diet or supplements OPINION
- Potassium Adjust intake to keep serum potassium normal; individualize for hyper- or hypokalemia OPINION; 2D
Sodium Less than 100 mmol/day (below 2.3 g/day) to lower BP and improve volume control 1B (CKD 3–5); 1C (5D and post-transplant)
- Sodium and proteinuria The same limit reduces proteinuria alongside medications (CKD 3–5) 2A
- Applying the guideline
Grades guide confidence, not rigidity. A 1A statement (protein restriction in stable CKD 3–5) is strong. An OPINION (bicarbonate 24–26 mmol/L) is expert practice that other bodies may differ on; KDIGO 2024 suggests treating acidosis when bicarbonate is below about 18 mmol/L.
The guideline deliberately avoids fixed milligram limits for potassium and phosphorus, which marks a shift from older "renal diet" numbers.
Know the populations. Diabetes, dialysis modality and transplant status change the protein statements.
Pair it with KDIGO for topics KDOQI 2020 does not cover, such as anemia drugs, MBD drugs and AKI (see section 16.2).